A mouse model for developing treatment for secondary liver tumors

Area of Science:

• Oncology
• Translational Research
• Medical Imaging

Background:

• Metastatic colorectal cancer (CRC) is a leading cause of cancer death, with liver involvement being common.
• Surgical resection is only an option for a minority of patients with liver metastases.
• Effective treatments for unresectable liver tumors are lacking, and survival rates remain low.

Purpose of the Study:

• To establish a reproducible murine model for evaluating therapies for secondary liver cancer.
• To mimic advanced cancer settings for preclinical drug testing.
• To assess the efficacy of irinotecan in a novel liver metastasis model.

Main Methods:

• Human colon cancer cells were injected into the portal vein of nude mice.
• Magnetic resonance imaging (MRI) was used for weekly monitoring of tumor growth and characteristics.
• Tumor growth, morphology, and biological characteristics were assessed and correlated with gross pathology.

Main Results:

• The model successfully generated liver metastases in 100% of mice, with reproducible tumor growth over time.
• MRI accurately tracked tumor progression and correlated well with necropsy findings.
• Irinotecan treatment doubled median survival (76-93 days) compared to vehicle control (43-46 days).

Conclusions:

• This murine model provides a rapid, inexpensive, and reliable platform for studying liver metastasis.
• The model, combined with small animal MRI, enables efficient therapeutic evaluation without invasive procedures.
• The findings support irinotecan's efficacy in treating liver metastases from colorectal cancer in this preclinical model.